Idalopirdine

DRUG4 trials

Sponsors

H. Lundbeck A/S

Conditions

Alzheimer's Disease

Phase 1

Positron Emission Tomography (PET) Study in Patients With Alzheimer's Disease

TerminatedNCT03307993

H. Lundbeck A/SAlzheimer's Disease

Start: 2017-09-22End: 2018-02-19Updated: 2018-04-04

Phase 3

Study of Idalopirdine in Patients With Mild - Moderate Alzheimer's Disease Treated With Donepezil

CompletedNCT01955161

H. Lundbeck A/SAlzheimer's Disease

Start: 2013-10-31End: 2016-07-31Updated: 2017-09-19

Idalopirdine in Patients With Mild-moderate Alzheimer's Disease Treated With Donepezil

CompletedNCT02006641

H. Lundbeck A/SAlzheimer's Disease

Start: 2014-02-28End: 2016-12-31Updated: 2018-02-20

Study of Idalopirdine in Patients With Mild - Moderate Alzheimer's Disease Treated With an Acetylcholinesterase Inhibitor

CompletedNCT02006654

H. Lundbeck A/SAlzheimer's Disease

Start: 2014-03-31End: 2017-01-31Updated: 2018-02-07

Related Papers

Enrichment factors for clinical trials in mild‐to‐moderate Alzheimer's disease

Alzheimer s & Dementia Translational Research & Clinical Interventions2019-01-0132 citations

Insights into globalization: comparison of patient characteristics and disease progression among geographic regions in a multinational Alzheimer's disease clinical program.

2018-11-2416 citations

Effect of Idalopirdine as Adjunct to Cholinesterase Inhibitors on Change in Cognition in Patients With Alzheimer Disease

JAMA2018-01-09159 citations

[DT‐02–02]: IDALOPIRDINE, A 5‐HT6 ANTAGONIST, AS ADJUNCTIVE THERAPY TO ACETYLCHOLINESTERASE INHIBITORS IN PATIENTS WITH MILD‐MODERATE ALZHEIMER's DISEASE: KEY OUTCOMES FROM THE STAR PHASE III PROGRAM

Alzheimer s & Dementia2017-07-01

P1‐056: Idalopirdine, A 5‐HT6 Antagonist in Phase III Development as Adjunctive Therapy to Cholinesterase Inhibitors in Patients with Mild‐to‐Moderate Alzheimer’s Disease: Baseline Data from the Ongoing Starshine Study

Alzheimer s & Dementia2016-07-01